PortalPublikationenMarkers of bone metabolism are affected by renal function an...

Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease

Standard

Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. / Doyon, Anke; Fischer, Dagmar-Christiane; Bayazit, Aysun Karabay; Canpolat, Nur; Duzova, Ali; Sözeri, Betül; Bacchetta, Justine; Balat, Ayse; Büscher, Anja; Candan, Cengiz; Cakar, Nilgun; Donmez, Osman; Dusek, Jiri; Heckel, Martina; Klaus, Günter; Mir, Sevgi; Özcelik, Gül; Sever, Lale; Shroff, Rukshana; Vidal, Enrico; Wühl, Elke; Gondan, Matthias; Melk, Anette; Querfeld, Uwe; Haffner, Dieter; Schaefer, Franz; 4C Study Consortium.

in: PLOS ONE, Jahrgang 10, Nr. 2, 06.02.2015, S. Art. e0113482.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Doyon, A, Fischer, D-C, Bayazit, AK, Canpolat, N, Duzova, A, Sözeri, B, Bacchetta, J, Balat, A, Büscher, A, Candan, C, Cakar, N, Donmez, O, Dusek, J, Heckel, M, Klaus, G, Mir, S, Özcelik, G, Sever, L, Shroff, R, Vidal, E, Wühl, E, Gondan, M, Melk, A, Querfeld, U, Haffner, D, Schaefer, F & 4C Study Consortium 2015, 'Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease', PLOS ONE, Jg. 10, Nr. 2, S. Art. e0113482. https://doi.org/10.1371/journal.pone.0113482

APA

Doyon, A., Fischer, D-C., Bayazit, A. K., Canpolat, N., Duzova, A., Sözeri, B., Bacchetta, J., Balat, A., Büscher, A., Candan, C., Cakar, N., Donmez, O., Dusek, J., Heckel, M., Klaus, G., Mir, S., Özcelik, G., Sever, L., Shroff, R., ... 4C Study Consortium (2015). Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLOS ONE, 10(2), Art. e0113482. https://doi.org/10.1371/journal.pone.0113482

Vancouver

Doyon A, Fischer D-C, Bayazit AK, Canpolat N, Duzova A, Sözeri B et al. Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLOS ONE. 2015 Feb 6;10(2):Art. e0113482. https://doi.org/10.1371/journal.pone.0113482

Bibtex

@article{b000a40e1a6542bb90e946befa64bd6b,
title = "Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease",
abstract = "OBJECTIVES: The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.METHODS: Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6-18 years with an estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.RESULTS: Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.CONCLUSION: Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.",
author = "Anke Doyon and Dagmar-Christiane Fischer and Bayazit, {Aysun Karabay} and Nur Canpolat and Ali Duzova and Bet{\"u}l S{\"o}zeri and Justine Bacchetta and Ayse Balat and Anja B{\"u}scher and Cengiz Candan and Nilgun Cakar and Osman Donmez and Jiri Dusek and Martina Heckel and G{\"u}nter Klaus and Sevgi Mir and G{\"u}l {\"O}zcelik and Lale Sever and Rukshana Shroff and Enrico Vidal and Elke W{\"u}hl and Matthias Gondan and Anette Melk and Uwe Querfeld and Dieter Haffner and Franz Schaefer and {4C Study Consortium}",
year = "2015",
month = feb,
day = "6",
doi = "10.1371/journal.pone.0113482",
language = "English",
volume = "10",
pages = "Art. e0113482",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease

AU - Doyon, Anke

AU - Fischer, Dagmar-Christiane

AU - Bayazit, Aysun Karabay

AU - Canpolat, Nur

AU - Duzova, Ali

AU - Sözeri, Betül

AU - Bacchetta, Justine

AU - Balat, Ayse

AU - Büscher, Anja

AU - Candan, Cengiz

AU - Cakar, Nilgun

AU - Donmez, Osman

AU - Dusek, Jiri

AU - Heckel, Martina

AU - Klaus, Günter

AU - Mir, Sevgi

AU - Özcelik, Gül

AU - Sever, Lale

AU - Shroff, Rukshana

AU - Vidal, Enrico

AU - Wühl, Elke

AU - Gondan, Matthias

AU - Melk, Anette

AU - Querfeld, Uwe

AU - Haffner, Dieter

AU - Schaefer, Franz

AU - 4C Study Consortium

PY - 2015/2/6

Y1 - 2015/2/6

N2 - OBJECTIVES: The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.METHODS: Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6-18 years with an estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.RESULTS: Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.CONCLUSION: Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.

AB - OBJECTIVES: The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.METHODS: Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6-18 years with an estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.RESULTS: Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.CONCLUSION: Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.

U2 - 10.1371/journal.pone.0113482

DO - 10.1371/journal.pone.0113482

M3 - SCORING: Journal article

C2 - 25659076

VL - 10

SP - Art. e0113482

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 2

ER -